26th Jun 2026 14:37
(Alliance News) - Scancell Holdings PLC on Friday confirmed it was in advanced talks to acquire Neuphoria Therapeutics Inc, which could facilitate a Nasdaq listing.
Scancell, an Oxford-based pharmaceutical company focused on cancer immunotherapies, said the talks are regarding a potential reverse merger transaction, whereby it would buy Nasdaq-listed biotechnology firm Neuphoria via an all-share transaction.
The acquisition could increase Scancell's profile with US specialist investors, the firm said.
Scancell added: "Concurrently, Scancell is in discussions regarding possible equity and debt financing to support a planned global phase 3 registrational study for its lead asset, iSCIB1+."
Sancell explained: "iSCIB1+, the lead product from their DNA ImmunoBody platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in a phase 2 trial in melanoma."
The company does not expect that the potential transaction would constitute a reverse takeover under London AIM market rules.
It added that there can be no certainty that a firm agreement with Neuphoria will be reacted.
Scancell shares fell 4.0% to 18.25 pence each on Friday afternoon in London, while Neuphoria shares opened 2.1% lower at USD4.27 each in New York.
By Tom Budszus, Alliance News slot editor
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Scancell Holdings